Condition
Overweight
Obesity
Locations
United States
Start date
31/08/2026
Identifiers
Trial ID NN9487-8023,
NCT number NCT07720271,
Eudract number Not Available
NCT number NCT07720271,
Eudract number Not Available
Summary
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as oral tablets once a day. Participants will either get zenagamtide (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Trial Overview:
Treatment
DRUG: zenagamtide
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Aug 31 2026 - Aug 22 2028
Participants
950
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.